Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy

Rieko Nakamura, Yoshiro Saikawa, Tetsuro Kubota, Atsushi Kumagai, Tsuyoshi Kiyota, Masaki Ohashi, Masashi Yoshida, Yoshihide Otani, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The clinical usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) chemosensitivity test (MTT assay; MTTA) in the selection of anticancer drugs against advanced gastric cancer (AGC) was evaluated. MTTA is widely used to predict patient responses to particular drugs, allowing for the selection of appropriate chemotherapeutic drugs and the avoidance of ineffective chemotherapeutic drugs, thereby improving patient survival. Since 1989, we have accumulated MTTA efficacy data from AGC patients. In this study, the present clinical roles of MTTA and the data from 202 patients with stage III or IV gastric cancer analyzed for survival outcome following surgery, with or without postoperative chemotherapy, evaluated by MTTA, are discussed. The patients were divided into 3 groups; an adapted group found to be sensitive to chemotherapy by MTTA, a non-adapted group found to be insensitive to chemotherapy by MTTA and a group that received no chemotherapy. For stage III gastric cancer patients, the adapted group had a statistically better survival rate compared to the other groups, while for stage IV patients, there was no difference in survival rate between any of the groups. However, further classification of stage IV patients as to the presence or absence of peritoneal dissemination (P) showed that the adapted group with P showed better prognoses than the other groups with P. The analysis of data collected since 2000 revealed that the 11 patients in the taxane-adapted group, who received chemotherapeutic regimens that included taxanes and were found to be sensitive to taxanes by MTTA, demonstrated better survival than the taxane non-adapted group (n=11) (p=0.045). In conclusion, MTTA results predicted patient prognoses, based on the selection of appropriate chemotherapy.

Original languageEnglish
Pages (from-to)1433-1437
Number of pages5
JournalAnticancer Research
Volume26
Issue number2 B
Publication statusPublished - 2006 Mar

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Drug Therapy
Taxoids
Pharmaceutical Preparations
Survival
Survival Rate
(5-methoxy-2-thienyl)thioacetic acid

Keywords

  • Adjuvant chemotherapy
  • Chemosensitivity test
  • Gastric cancer
  • MTT assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakamura, R., Saikawa, Y., Kubota, T., Kumagai, A., Kiyota, T., Ohashi, M., ... Kitajima, M. (2006). Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. Anticancer Research, 26(2 B), 1433-1437.

Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. / Nakamura, Rieko; Saikawa, Yoshiro; Kubota, Tetsuro; Kumagai, Atsushi; Kiyota, Tsuyoshi; Ohashi, Masaki; Yoshida, Masashi; Otani, Yoshihide; Kumai, Koichiro; Kitajima, Masaki.

In: Anticancer Research, Vol. 26, No. 2 B, 03.2006, p. 1433-1437.

Research output: Contribution to journalArticle

Nakamura, R, Saikawa, Y, Kubota, T, Kumagai, A, Kiyota, T, Ohashi, M, Yoshida, M, Otani, Y, Kumai, K & Kitajima, M 2006, 'Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy', Anticancer Research, vol. 26, no. 2 B, pp. 1433-1437.
Nakamura, Rieko ; Saikawa, Yoshiro ; Kubota, Tetsuro ; Kumagai, Atsushi ; Kiyota, Tsuyoshi ; Ohashi, Masaki ; Yoshida, Masashi ; Otani, Yoshihide ; Kumai, Koichiro ; Kitajima, Masaki. / Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. In: Anticancer Research. 2006 ; Vol. 26, No. 2 B. pp. 1433-1437.
@article{77be36373f3346cb8b7167cded7bf06c,
title = "Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy",
abstract = "The clinical usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) chemosensitivity test (MTT assay; MTTA) in the selection of anticancer drugs against advanced gastric cancer (AGC) was evaluated. MTTA is widely used to predict patient responses to particular drugs, allowing for the selection of appropriate chemotherapeutic drugs and the avoidance of ineffective chemotherapeutic drugs, thereby improving patient survival. Since 1989, we have accumulated MTTA efficacy data from AGC patients. In this study, the present clinical roles of MTTA and the data from 202 patients with stage III or IV gastric cancer analyzed for survival outcome following surgery, with or without postoperative chemotherapy, evaluated by MTTA, are discussed. The patients were divided into 3 groups; an adapted group found to be sensitive to chemotherapy by MTTA, a non-adapted group found to be insensitive to chemotherapy by MTTA and a group that received no chemotherapy. For stage III gastric cancer patients, the adapted group had a statistically better survival rate compared to the other groups, while for stage IV patients, there was no difference in survival rate between any of the groups. However, further classification of stage IV patients as to the presence or absence of peritoneal dissemination (P) showed that the adapted group with P showed better prognoses than the other groups with P. The analysis of data collected since 2000 revealed that the 11 patients in the taxane-adapted group, who received chemotherapeutic regimens that included taxanes and were found to be sensitive to taxanes by MTTA, demonstrated better survival than the taxane non-adapted group (n=11) (p=0.045). In conclusion, MTTA results predicted patient prognoses, based on the selection of appropriate chemotherapy.",
keywords = "Adjuvant chemotherapy, Chemosensitivity test, Gastric cancer, MTT assay",
author = "Rieko Nakamura and Yoshiro Saikawa and Tetsuro Kubota and Atsushi Kumagai and Tsuyoshi Kiyota and Masaki Ohashi and Masashi Yoshida and Yoshihide Otani and Koichiro Kumai and Masaki Kitajima",
year = "2006",
month = "3",
language = "English",
volume = "26",
pages = "1433--1437",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy

AU - Nakamura, Rieko

AU - Saikawa, Yoshiro

AU - Kubota, Tetsuro

AU - Kumagai, Atsushi

AU - Kiyota, Tsuyoshi

AU - Ohashi, Masaki

AU - Yoshida, Masashi

AU - Otani, Yoshihide

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2006/3

Y1 - 2006/3

N2 - The clinical usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) chemosensitivity test (MTT assay; MTTA) in the selection of anticancer drugs against advanced gastric cancer (AGC) was evaluated. MTTA is widely used to predict patient responses to particular drugs, allowing for the selection of appropriate chemotherapeutic drugs and the avoidance of ineffective chemotherapeutic drugs, thereby improving patient survival. Since 1989, we have accumulated MTTA efficacy data from AGC patients. In this study, the present clinical roles of MTTA and the data from 202 patients with stage III or IV gastric cancer analyzed for survival outcome following surgery, with or without postoperative chemotherapy, evaluated by MTTA, are discussed. The patients were divided into 3 groups; an adapted group found to be sensitive to chemotherapy by MTTA, a non-adapted group found to be insensitive to chemotherapy by MTTA and a group that received no chemotherapy. For stage III gastric cancer patients, the adapted group had a statistically better survival rate compared to the other groups, while for stage IV patients, there was no difference in survival rate between any of the groups. However, further classification of stage IV patients as to the presence or absence of peritoneal dissemination (P) showed that the adapted group with P showed better prognoses than the other groups with P. The analysis of data collected since 2000 revealed that the 11 patients in the taxane-adapted group, who received chemotherapeutic regimens that included taxanes and were found to be sensitive to taxanes by MTTA, demonstrated better survival than the taxane non-adapted group (n=11) (p=0.045). In conclusion, MTTA results predicted patient prognoses, based on the selection of appropriate chemotherapy.

AB - The clinical usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) chemosensitivity test (MTT assay; MTTA) in the selection of anticancer drugs against advanced gastric cancer (AGC) was evaluated. MTTA is widely used to predict patient responses to particular drugs, allowing for the selection of appropriate chemotherapeutic drugs and the avoidance of ineffective chemotherapeutic drugs, thereby improving patient survival. Since 1989, we have accumulated MTTA efficacy data from AGC patients. In this study, the present clinical roles of MTTA and the data from 202 patients with stage III or IV gastric cancer analyzed for survival outcome following surgery, with or without postoperative chemotherapy, evaluated by MTTA, are discussed. The patients were divided into 3 groups; an adapted group found to be sensitive to chemotherapy by MTTA, a non-adapted group found to be insensitive to chemotherapy by MTTA and a group that received no chemotherapy. For stage III gastric cancer patients, the adapted group had a statistically better survival rate compared to the other groups, while for stage IV patients, there was no difference in survival rate between any of the groups. However, further classification of stage IV patients as to the presence or absence of peritoneal dissemination (P) showed that the adapted group with P showed better prognoses than the other groups with P. The analysis of data collected since 2000 revealed that the 11 patients in the taxane-adapted group, who received chemotherapeutic regimens that included taxanes and were found to be sensitive to taxanes by MTTA, demonstrated better survival than the taxane non-adapted group (n=11) (p=0.045). In conclusion, MTTA results predicted patient prognoses, based on the selection of appropriate chemotherapy.

KW - Adjuvant chemotherapy

KW - Chemosensitivity test

KW - Gastric cancer

KW - MTT assay

UR - http://www.scopus.com/inward/record.url?scp=33645832583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645832583&partnerID=8YFLogxK

M3 - Article

C2 - 16619555

AN - SCOPUS:33645832583

VL - 26

SP - 1433

EP - 1437

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -